Navigation Links
Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
Date:9/25/2007

SAN DIEGO, Sept. 25 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that enrollment is complete in its Chemophase(R) Phase I/IIa clinical trial for the treatment of superficial bladder cancer. The Company began dosing patients in this trial in April of last year, following the successful completion of the initial Phase I trial of a single-administration of Chemophase and mitomycin. Patient enrollment in this Phase I/IIa trial required stepwise enrollment by escalating dose cohort, with a pause for safety evaluation required after the last patient in the previous cohort had completed at least the first four of the six weekly study drug instillations. Chemophase is a novel recombinant investigational therapeutic being developed to enhance the delivery of chemotherapy.

The Chemophase Phase I/IIa clinical trial is a multi-center, open label, nonrandomized study to evaluate multiple intravesical (into the bladder) administrations of Chemophase along with the widely used anticancer drug mitomycin in patients with superficial bladder cancer. This dose-finding Phase I/IIa study enrolled 27 patients with superficial bladder cancer. The objectives of the study included determining the maximum tolerated dose (MTD) and dose-limiting toxicities, if any, of escalating doses of mitomycin and then Chemophase in combination with mitomycin administered as weekly intravesical instillations for six weeks, consistent with the usual standard of care; establishing the optimal dose of Chemophase with mitomycin to be recommended for future studies; and observing patients for any preliminary evidence of anti-tumor activity of this combination therapy. The trial is ongoing, as the most recently enrolled patients complete their initial six weekly treatments, all patients are monitored according to standard of care for tumor recurrence, and the patients enrolled at the MTD cohort continue maintenance dosing until the end of Year 2 of the study.

"We are pleased to have reached another important milestone in the development of Chemophase, which is proceeding along our expected timeline. We hope to announce interim data from this ongoing trial during the first half of next year," said Jonathan Lim, MD, Halozyme's President and CEO.

In the Chemophase Phase I trial, pharmacokinetic data were obtained from the plasma of five bladder cancer patients dosed intravesically with 20,000 units of Chemophase along with 40 mg of mitomycin. The observed plasma levels of mitomycin were less than 1/40th of the levels reported to be predictive of suppression of white blood cell production. The study was conducted at BCG Oncology in Phoenix, Arizona under the supervision of Donald L. Lamm, MD, the principal investigator.

The American Cancer Society estimates that there are approximately 67,000 new cases of bladder cancer diagnosed in the United States annually. At any given time, it is estimated that there are more than 500,000 bladder cancer patients in the U.S. According to Botteman et al., (PharmacoEconomics 2003), bladder cancer is the fifth most expensive cancer to treat. The initial treatment of this cancer is surgical removal of the tumor. Because of the high frequency of early recurrences of the tumor, patients are usually prescribed additional therapy to prevent or delay such recurrences. This additional therapy generally consists of immunotherapy or chemotherapy drugs instilled directly into the bladder.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology, and dermatology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its first partnership is with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets. In addition, the company has received FDA approval for two products: Cumulase(R) and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter Healthcare Corporation. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the development of Chemophase and the release of interim data related to current clinical trials) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact Investor Relations Contact

David A. Ramsay Don Markley

Chief Financial Officer Lippert/Heilshorn & Associates

(858) 794-8881 (310) 691-7100

dramsay@halozyme.com dmarkley@lhai.com

Media Contacts

Karen Sparks / Joleen Schultz Mentus

(858) 455-5500, x275/x215

karen@mentus.com

jschultz@mentus.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 Een app die ... zij collectief patiënten kunnen behandelen, hun kennis kunnen delen ... achter de nieuwe en revolutionaire MDLinking App, ontwikkeld door ... vaatchirurg dr. Hans Flu en oncologisch chirurg dr. ... beschikbaar is, wordt op dinsdag 24 mei officieel gepresenteerd ...
(Date:5/23/2016)... 23, 2016 Transparency Market Research ... Pancreatic Insufficiency Market - Global Industry Analysis, Size, Share, ... to the report, the exocrine pancreatic insufficiency market is ... 2015 to 2023 to reach US$2.85 Bn by 2023. ... characterized by the deficiency of the exocrine pancreatic enzymes, ...
(Date:5/23/2016)... 2016 Non-invasive diagnostic test realizes ... diseases; ,Technology to be presented at Yissum’s booth, at ... Development Company of the Hebrew University of Jerusalem ... with Aurum Ventures MKI, the technology investment arm of ... diagnostic approach for early detection of multiple diseases by ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow ... its Advisory Board. Joining the Grow Healthy Advisory Board team ... them embody the mission of our organization and bring talent, expertise ... them as we continue to expand our footprint as the leader ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... A newly ... rely heavily on their access to trusted resources, both in face-to-face interactions and online. ... Men of Color,” researchers concluded that the creative use of mobile digital devices can ...
(Date:5/24/2016)... DC (PRWEB) , ... May 24, 2016 , ... ... consumers for 2016 increased by 9.3 million people, or 10% over last year, ... number of people covered under group policies was comparatively stable, with a slight ...
(Date:5/24/2016)... ... 2016 , ... Controlling and maintaining the home’s water heater just got infinitely ... Water Heater Controller , a first-of-its-kind system that enables remote and convenient control of ... thermostat does for HVAC systems, Aquanta gives users a much more efficient, versatile way ...
(Date:5/24/2016)... ... ... The Dream Builders Project, a 501(c)3 nonprofit organization based in Los Angeles, ... Mexico on Saturday, May 21st. The volunteers took the children out for the day ... 15 volunteers traveled from Los Angeles to Tijuana, Mexico for the day in the ...
Breaking Medicine News(10 mins):